Holen Sie sich die Stockscreener-App
233.85
0.89%
1.775
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$232.08
Offen:
$233.66
24-Stunden-Volumen:
1.83M
Relative Volume:
0.28
Marktkapitalisierung:
$413.67B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.19B
KGV:
99.03
EPS:
2.3614
Netto-Cashflow:
$17.82B
1W Leistung:
+2.04%
1M Leistung:
+3.77%
6M Leistung:
+10.49%
1J Leistung:
+12.02%
1-Tages-Spanne:
$231.90
$235.66
1-Wochen-Bereich:
$221.12
$235.66
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, NVS, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
233.96 | 410.36B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
1,036.43 | 992.40B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
248.62 | 598.69B | 94.19B | 26.80B | 19.70B | 11.05 |
|
NVS
Novartis Ag Adr
|
166.08 | 321.75B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
204.27 | 323.26B | 58.80B | 10.24B | 8.98B | 3.2788 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Inc. $ABBV Shares Sold by R Squared Ltd - MarketBeat
AbbVie Inc. $ABBV Shares Sold by APG Asset Management N.V. - MarketBeat
Westfield Capital Management Co. LP Takes $1.84 Million Position in AbbVie Inc. $ABBV - MarketBeat
Harvest Portfolios Group Inc. Has $66.12 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Huntington National Bank Purchases 24,310 Shares of AbbVie Inc. $ABBV - MarketBeat
American Century Companies Inc. Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 3.1%Time to Buy? - MarketBeat
AbbVie Executive Sells Over $5 Million in Company Stock - TradingView
AbbVie Inc Stock Closed Up by 3.12% on Feb 27: What Signal Does It Send? - TradingKey
AbbVie Loses Challenge to Contract Pharmacy Law in Tennessee - Bloomberg Law News
AbbVie | 2/27/26 - ktnv.com
One in Three Rheumatologists View BMS’ Sotyktu as a Substantial Advance in Psoriatic Arthritis Ahead of March 6 FDA Decision, According to Spherix Global Insights Data - GlobeNewswire Inc.
AbbVie’s XEN45 Glaucoma Study Signals New Angle in Eye Care Strategy - TipRanks
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term - Nasdaq
Xponance Inc. Grows Holdings in AbbVie Inc. $ABBV - MarketBeat
Generali Investments Management Co LLC Raises Stake in AbbVie Inc. $ABBV - MarketBeat
Handelsbanken Fonder AB Decreases Stake in AbbVie Inc. $ABBV - MarketBeat
Erste Asset Management GmbH Cuts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AXQ Capital LP Cuts Stake in AbbVie Inc. $ABBV - MarketBeat
Andra AP fonden Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Does AbbVie (ABBV) Share Price Reflect Its DCF Value Despite High P/E Multiple - simplywall.st
GUBRA: Record revenue and profit in 2025, led by AbbVie deal and strong Biotech performance - TradingView
GUBRA: Record earnings from AbbVie deal, strong cash, and major ESG progress define 2025 - TradingView
GUBRA: Record earnings and cash flow in 2025 fueled by AbbVie deal and robust Biotech pipeline - TradingView
AbbVie (ABBV) Announces $7.95 Billion Senior Notes Offering - GuruFocus
AbbVie Announces $7.5 Billion Senior Notes Offering - TipRanks
AbbVie prices $7.95B senior notes offering across maturities to refinance debt - TradingView
Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program - statnews.com
Where Will AbbVie Be in 5 Years? - The Globe and Mail
DOJ Supports AbbVie in Suit Over Colorado’s Drug Discount Law - Bloomberg Law News
Thornburg Investment Management Inc. Has $93.02 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
US Bancorp DE Sells 30,755 Shares of AbbVie Inc. $ABBV - MarketBeat
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie - Seeking Alpha
Intech Investment Management LLC Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
ABBV SEC FilingsAbbvie Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AbbVie’s CLL Breakthrough And US$380m Build Out Test Valuation - Yahoo Finance
RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears - Finviz
Here are Wednesday’s top Wall Street analyst research calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and more - MSN
AbbVie Stock Near Highs After Fresh Analyst Calls: Buy The Dip Or Take Profits? - AD HOC NEWS
Key facts: RBC Capital rates AbbVie 'Outperform'; $8B notes offering filed - TradingView
RBC Capital Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation - Nasdaq
RBC Capital Markets Sees Growth Potential for AbbVie (ABBV) - GuruFocus
AbbVie (ABBV) Stock: What RBC’s New Outperform Rating Means for Investors - CoinCentral
AbbVie a new outperform at RBC Capital Markets on durable growth - Seeking Alpha
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - PharmiWeb.com
RBC Capital Initiates Coverage on AbbVie (ABBV) with Outperform Rating | ABBV Stock News - GuruFocus
Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie - Investing.com Australia
AbbVie’s $100B US deal and FDA reforms highlight growing focus on domestic manufacturing - The Pharma Letter
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested - Benzinga
AbbVie files for seven-part notes offering of up to $8 billion - marketscreener.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More - 24/7 Wall St.
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):